Top

Current Diabetes Reports

Published in:

01-09-2021 | Diabetic Retinopathy | Microvascular Complications—Retinopathy (R Channa, Section Editor)

Management of Complications and Vision Loss from Proliferative Diabetic Retinopathy

Authors: Gordon S. Crabtree, Jonathan S. Chang

Published in: Current Diabetes Reports | Issue 9/2021

Abstract

Purpose of Review

Diabetes can be associated with profound visual loss due to several mechanisms. As the duration of diabetes and blood glucose levels increase, these changes become more severe. The proliferation of new blood vessels, vitreous hemorrhage, and tractional retinal detachments may ultimately result and can be devastating to visual function. New advances, including anti-vascular endothelial growth factor (VEGF) medications and innovative microsurgical instruments, have provided additional methods for the management of diabetic retinopathy in the clinic and in the operating room, leading to improved outcomes.

Recent Findings

Advances in earlier treatment of proliferative diabetic retinopathy, especially with anti-VEGF injections, allow for a reduction in severity, improved vision, and more controlled and successful surgery. Modern surgical techniques and instrumentation have also allowed for improved patient outcomes. Future research into sustained delivery and release of anti-VEGF, reducing the need for frequent in-office injections, may prove to be additionally beneficial.

Summary

Over the last decade, anti-VEGF has become an increasingly common treatment modality for the management of proliferative diabetic retinopathy, vitreous hemorrhages, and tractional retinal detachments. Further research is needed to determine the ideal method of delivery and timing of the treatment.

Fong DS, Aiello LP, Ferris FL, Klein R. Diabetic retinopathy. Diabetes Care. 2004;27(10):2540–53. https://doi.org/10.2337/diacare.27.10.2540.CrossRefPubMed

Congdon NG, Friedman DS, Lietman T. Important causes of visual impairment in the world today. JAMA. 2003;290(15):2057–60. https://doi.org/10.1001/jama.290.15.2057.CrossRefPubMed

Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol. 1984;102(4):520–6. https://doi.org/10.1001/archopht.1984.01040030398010.CrossRefPubMed

LeCaire TJ, Palta M, Klein R, Klein BE, Cruickshanks KJ. Assessing progress in retinopathy outcomes in type 1 diabetes: comparing findings from the Wisconsin Diabetes Registry Study and the Wisconsin Epidemiologic Study of Diabetic Retinopathy. Diabetes Care. 2013;36(3):631–7. https://doi.org/10.2337/dc12-0863.CrossRefPubMedPubMedCentral

Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophthalmol. 1984;102(4):527–32. https://doi.org/10.1001/archopht.1984.01040030405011.CrossRefPubMed

Zhang X, Saaddine JB, Chou CF, Cotch MF, Cheng YJ, Geiss LS, et al. Prevalence of diabetic retinopathy in the United States, 2005–2008. JAMA. 2010;304(6):649–56. https://doi.org/10.1001/jama.2010.1111.

Kempen JH, O'Colmain BJ, Leske MC, Haffner SM, Klein R, Moss SE, et al. The prevalence of diabetic retinopathy among adults in the United States. Arch Ophthalmol. 2004;122(4):552–63. https://doi.org/10.1001/archopht.122.4.552.

Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 1991;98(5 Suppl):766-85.

Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet. 2010;376(9735):124–36. https://doi.org/10.1016/s0140-6736(09)62124-3.CrossRefPubMed

10.

Nathan DM, Genuth S, Lachin J, Cleary P, Crofford O, Davis M, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977–86. https://doi.org/10.1056/nejm199309303291401.CrossRefPubMed

11.

Indications for photocoagulation treatment of diabetic retinopathy: Diabetic Retinopathy Study Report no. 14. The Diabetic Retinopathy Study Research Group. Int Ophthalmol Clin 1987;27(4):239-53. https://doi.org/10.1097/00004397-198702740-00004.

12.

Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. The Diabetic Retinopathy Study Research Group. Ophthalmology 1981;88(7):583-600.

13.

Flynn HW Jr, Chew EY, Simons BD, Barton FB, Remaley NA, Ferris FL 3rd. Pars plana vitrectomy in the Early Treatment Diabetic Retinopathy Study. ETDRS report number 17. The Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology. 1992;99(9):1351–7. https://doi.org/10.1016/s0161-6420(92)31779-8.CrossRefPubMed

14.

Landers MB 3rd, Stefansson E, Wolbarsht ML. Panretinal photocoagulation and retinal oxygenation. Retina. 1982;2(3):167–75. https://doi.org/10.1097/00006982-198200230-00007.CrossRefPubMed

15.

Nguyen QD, Brown DM, Marcus DM, Boyer DS, Patel S, Feiner L, et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012;119(4):789–801. https://doi.org/10.1016/j.ophtha.2011.12.039.

16.

Ip MS, Domalpally A, Hopkins JJ, Wong P, Ehrlich JS. Long-term effects of ranibizumab on diabetic retinopathy severity and progression. Arch Ophthalmol. 2012;130(9):1145–52. https://doi.org/10.1001/archophthalmol.2012.1043.CrossRefPubMed

17.

Gross JG, Glassman AR, Jampol LM, Inusah S, Aiello LP, Antoszyk AN, et al. Panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial. JAMA. 2015;314(20):2137–46. https://doi.org/10.1001/jama.2015.15217.

18.

Gross JG, Glassman AR, Liu D, Sun JK, Antoszyk AN, Baker CW, et al. Five-year outcomes of panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial. JAMA Ophthalmol. 2018;136(10):1138–48. https://doi.org/10.1001/jamaophthalmol.2018.3255.

19.

Maguire MG, Liu D, Glassman AR, Jampol LM, Johnson CA, Baker CW, et al. Visual field changes over 5 years in patients treated with panretinal photocoagulation or ranibizumab for proliferative diabetic retinopathy. JAMA Ophthalmol. 2020;138(3):285–93. https://doi.org/10.1001/jamaophthalmol.2019.5939.

20.

Berrocal MH, Acaba LA, Chenworth ML. Surgical innovations in the treatment of diabetic macular edema and diabetic retinopathy. Curr Diab Rep. 2019;19(10):106. https://doi.org/10.1007/s11892-019-1210-x.

21.

Wang JH, Roberts GE, Liu GS. Updates on gene therapy for diabetic retinopathy. Curr Diab Rep. 2020;20(7):22. https://doi.org/10.1007/s11892-020-01308-w.CrossRefPubMedPubMedCentral

22.•

Bourry J, Courteville H, Ramdane N, Drumez E, Duhamel A, Subtil D, et al. Progression of diabetic retinopathy and predictors of its development and progression during pregnancy in patients with type 1 diabetes: a report of 499 pregnancies. Diabetes Care. 2021;44(1):181–7. https://doi.org/10.2337/dc20-0904. This study retrospectively evaluated progression of diabetic in type 1 diabetics with pregnancy and showed that the rate of diabetic retinopathy progression was 22%, and 25% developed diabetic retinopathy with no prior retinopathy present.

23.

Robinson GE. Pregnancy loss. Best Pract Res Clin Obstet Gynaecol. 2014;28(1):169–78. https://doi.org/10.1016/j.bpobgyn.2013.08.012.CrossRefPubMed

24.

Polizzi S, Mahajan VB. Intravitreal anti-VEGF injections in pregnancy: case series and review of literature. J Ocul Pharmacol Ther. 2015;31(10):605–10. https://doi.org/10.1089/jop.2015.0056.CrossRefPubMedPubMedCentral

25.••

Bhavsar AR, Torres K, Glassman AR, Jampol LM, Kinyoun JL. Evaluation of results 1 year following short-term use of ranibizumab for vitreous hemorrhage due to proliferative diabetic retinopathy. JAMA Ophthalmol. 2014;132(7):889–90. https://doi.org/10.1001/jamaophthalmol.2014.287. This prospective multi-center study evaluated use of intravitreal ranibizumab for vitreous hemorrhage secondary to proliferative diabetic retinopathy. It showed that treatment allowed for more prompt laser, patients still may require vitrectomy surgery for non-clearing vitreous hemorrhage.

26.••

Antoszyk AN, Glassman AR, Beaulieu WT, Jampol LM, Jhaveri CD, Punjabi OS, et al. Effect of intravitreous aflibercept vs vitrectomy with panretinal photocoagulation on visual acuity in patients with vitreous hemorrhage from proliferative diabetic retinopathy: a randomized clinical trial. JAMA. 2020;324(23):2383–95. https://doi.org/10.1001/jama.2020.23027. This prospective multi-center study evaluated use of intravitreal aflibercept for vitreous hemorrhage secondary to proliferative diabetic retinopathy. It showed that mean visual acuity in eyes treated with aflibercept was similar to those that underwent vitrectomy however the study may be underpowered.

27.

Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy. Two-year results of a randomized trial. Diabetic Retinopathy Vitrectomy Study report 2. The Diabetic Retinopathy Vitrectomy Study Research Group. Arch Ophthalmol. 1985;103(11):1644-52.

28.

Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy. Four-year results of a randomized trial: Diabetic Retinopathy Vitrectomy Study Report 5. Arch Ophthalmol 1990;108(7):958-64. https://doi.org/10.1001/archopht.1990.01070090060040.

29.

Early vitrectomy for severe proliferative diabetic retinopathy in eyes with useful vision. Clinical application of results of a randomized trial--Diabetic Retinopathy Vitrectomy Study Report 4. The Diabetic Retinopathy Vitrectomy Study Research Group. Ophthalmology 1988;95(10):1321-34. https://doi.org/10.1016/s0161-6420(88)33014-9.

30.

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324(7329):71-86. https://doi.org/10.1136/bmj.324.7329.71.

31.

Banerjee S, Denniston AK, Gibson JM, Dodson PM. Does cardiovascular therapy affect the onset and recurrence of preretinal and vitreous haemorrhage in diabetic eye disease? Eye (Lond). 2004;18(8):821–5. https://doi.org/10.1038/sj.eye.6701338.CrossRef

32.

Chew EY, Klein ML, Murphy RP, Remaley NA, Ferris FL. Effects of aspirin on vitreous/preretinal hemorrhage in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report no. 20. Arch Ophthalmol. 1995;113(1):52–5. https://doi.org/10.1001/archopht.1995.01100010054020.CrossRefPubMed

33.

Aiello LP, Cahill MT, Wong JS. Systemic considerations in the management of diabetic retinopathy. Am J Ophthalmol. 2001;132(5):760–76. https://doi.org/10.1016/s0002-9394(01)01124-2.CrossRefPubMed

34.

Vaz-Pereira S, Dansingani KK, Chen KC, Cooney MJ, Klancnik JM, Engelbert M. Tomographic relationships between retinal neovascularization and the posterior vitreous in proliferative diabetic retinopathy. Retina. 2017;37(7):1287–96. https://doi.org/10.1097/IAE.0000000000001336.CrossRefPubMed

35.

Two-year course of visual acuity in severe proliferative diabetic retinopathy with conventional management. Diabetic Retinopathy Vitrectomy Study (DRVS) report #1. Ophthalmology. 1985;92(4):492-502. https://doi.org/10.1016/s0161-6420(85)34002-2.

36.

Rice TA, Michels RG, Rice EF. Vitrectomy for diabetic traction retinal detachment involving the macula. Am J Ophthalmol. 1983;95(1):22–33. https://doi.org/10.1016/0002-9394(83)90330-6.CrossRefPubMed

37.

Thompson JT, de Bustros S, Michels RG, Rice TA. Results and prognostic factors in vitrectomy for diabetic traction retinal detachment of the macula. Arch Ophthalmol. 1987;105(4):497–502. https://doi.org/10.1001/archopht.1987.01060040067035.CrossRefPubMed

38.

Williams DF, Williams GA, Hartz A, Mieler WF, Abrams GW, Aaberg TM. Results of vitrectomy for diabetic traction retinal detachments using the en bloc excision technique. Ophthalmology. 1989;96(6):752–8. https://doi.org/10.1016/s0161-6420(89)32813-2.CrossRefPubMed

39.

Han DP, Murphy ML, Mieler WF. A modified en bloc excision technique during vitrectomy for diabetic traction retinal detachment. Results and complications Ophthalmology. 1994;101(5):803–8. https://doi.org/10.1016/s0161-6420(94)31255-3.CrossRefPubMed

40.•

Sokol JT, Schechet SA, Rosen DT, Ferenchak K, Dawood S, Skondra D. Outcomes of vitrectomy for diabetic tractional retinal detachment in Chicago's county health system. PLoS One. 2019;14(8):e0220726. https://doi.org/10.1371/journal.pone.0220726. This retrospective trial showed that 98.6% of patients undergoing vitrectomy for complex traction retinal detachment secondary to diabetic retinopathy had reattachment with a single surgery.

41.•

Al-Khersan H, Venincasa MJ, Kloosterboer A, Sridhar J, Smiddy WE, Townsend JH, et al. Pars plana vitrectomy reoperations for complications of proliferative diabetic retinopathy. Clin Ophthalmol. 2020;14:1559–63. https://doi.org/10.2147/opth.s252285. This retrospective trial of patients undergoing vitrectomy for complications of proliferative diabetic retinopathy showed 28% required reoperation.

42.•

Storey PP, Ter-Zakarian A, Philander SA. Olmos de Koo L, George M, Humayun MS et al. Visual and anatomical outcomes after diabetic traction and traction-rhegmatogenous retinal detachment repair. Retina. 2018;38(10):1913–9. https://doi.org/10.1097/iae.0000000000001793. This retrospective trial of patients with traction retinal detachments secondary to proliferative diabetic retinopathy showed that 87.6% had successful reattachment after a single surgery.

43.

Lahey JM, Francis RR, Kearney JJ, Cheung M. Combining phacoemulsification and vitrectomy in patients with proliferative diabetic retinopathy. Curr Opin Ophthalmol. 2004;15(3):192–6. https://doi.org/10.1097/01.icu.0000120676.27548.0e.CrossRefPubMed

44.

Abrams GW, Williams GA. "En bloc" excision of diabetic membranes. Am J Ophthalmol. 1987;103(3 Pt 1):302–8.CrossRef

45.

Gupta B, Wong R, Sivaprasad S, Williamson TH. Surgical and visual outcome following 20-gauge vitrectomy in proliferative diabetic retinopathy over a 10-year period, evidence for change in practice. Eye (Lond). 2012;26(4):576–82. https://doi.org/10.1038/eye.2011.348.CrossRef

46.

Meredith TA, Kaplan HJ, Aaberg TM. Pars plana vitrectomy techniques for relief of epiretinal traction by membrane segmentation. Am J Ophthalmol. 1980;89(3):408–13. https://doi.org/10.1016/0002-9394(80)90012-4.CrossRefPubMed

47.

Issa SA, Connor A, Habib M, Steel DH. Comparison of retinal breaks observed during 23 gauge transconjunctival vitrectomy versus conventional 20 gauge surgery for proliferative diabetic retinopathy. Clin Ophthalmol. 2011;5:109–14. https://doi.org/10.2147/opth.s16414.CrossRefPubMedPubMedCentral

48.

Fortun JA, Hubbard GB 3rd. New viscodissection instrument for use with microincisional vitrectomy in the treatment of diabetic tractional retinal detachments. Arch Ophthalmol. 2011;129(3):352–5. https://doi.org/10.1001/archophthalmol.2011.15.CrossRefPubMed

49.

Oshima Y, Awh CC, Tano Y. Self-retaining 27-gauge transconjunctival chandelier endoillumination for panoramic viewing during vitreous surgery. Am J Ophthalmol. 2007;143(1):166–7. https://doi.org/10.1016/j.ajo.2006.07.051.CrossRefPubMed

50.

Williams GA, Abrams GW, Mieler WF. Illuminated retinal picks for vitreous surgery. Arch Ophthalmol. 1989;107(7):1086. https://doi.org/10.1001/archopht.1989.01070020148051.CrossRefPubMed

51.

Imamura Y, Minami M, Ueki M, Satoh B, Ikeda T. Use of perfluorocarbon liquid during vitrectomy for severe proliferative diabetic retinopathy. Br J Ophthalmol. 2003;87(5):563–6. https://doi.org/10.1136/bjo.87.5.563.CrossRefPubMedPubMedCentral

52.

Farah ME, Maia M, Rodrigues EB. Dyes in ocular surgery: principles for use in chromovitrectomy. Am J Ophthalmol. 2009;148(3):332–40. https://doi.org/10.1016/j.ajo.2009.04.003.CrossRefPubMed

53.

Talcott KE, Adam MK, Sioufi K, Aderman CM, Ali FS, Mellen PL, et al. Comparison of a three-dimensional heads-up display surgical platform with a standard operating microscope for macular surgery. Ophthalmol Retina. 2019;3(3):244–51. https://doi.org/10.1016/j.oret.2018.10.016.

54.

Ehlers JP, Goshe J, Dupps WJ, Kaiser PK, Singh RP, Gans R, et al. Determination of feasibility and utility of microscope-integrated optical coherence tomography during ophthalmic surgery: the DISCOVER Study RESCAN Results. JAMA Ophthalmol. 2015;133(10):1124–32. https://doi.org/10.1001/jamaophthalmol.2015.2376.

55.

Imai H, Tetsumoto A, Inoue S, Takano F, Yamada H, Hayashida M, et al. Intraoperative three-dimensional fluorescein angiography-guided pars plana vitrectomy for the treatment of proliferative diabetic retinopathy: the maximized utility of the digital assisted vitrectomy. Retina. 2020. https://doi.org/10.1097/IAE.0000000000002805.

56.

Auriol S, Pagot-Mathis V, Mahieu L, Lemoine C, Mathis A. Efficacy and safety of heavy silicone oil Densiron 68 in the treatment of complicated retinal detachment with large inferior retinectomy. Graefes Arch Clin Exp Ophthalmol. 2008;246(10):1383–9. https://doi.org/10.1007/s00417-008-0876-6.CrossRefPubMed

57.

Yang CM, Yeh PT, Yang CH. Intravitreal long-acting gas in the prevention of early postoperative vitreous hemorrhage in diabetic vitrectomy. Ophthalmology. 2007;114(4):710–5. https://doi.org/10.1016/j.ophtha.2006.07.047.CrossRefPubMed

58.

Shen YD, Yang CM. Extended silicone oil tamponade in primary vitrectomy for complex retinal detachment in proliferative diabetic retinopathy: a long-term follow-up study. Eur J Ophthalmol. 2007;17(6):954–60. https://doi.org/10.1177/112067210701700614.CrossRefPubMed

59.

Smith JM, Steel DH. Anti-vascular endothelial growth factor for prevention of postoperative vitreous cavity haemorrhage after vitrectomy for proliferative diabetic retinopathy. Cochrane Database Syst Rev. 2011;5:Cd008214. https://doi.org/10.1002/14651858.CD008214.pub2.CrossRef

60.•

Arevalo JF, Lasave AF, Kozak I, Al Rashaed S, Al Kahtani E, Maia M, et al. Preoperative bevacizumab for tractional retinal detachment in proliferative diabetic retinopathy: a prospective randomized clinical trial. Am J Ophthalmol. 2019;207:279–87. https://doi.org/10.1016/j.ajo.2019.05.007. This randomized, multi-center, prospective trial showed improved surgical time and reduced bleeding in patients receiving anti-VEGF therapy prior to vitrectomy for complications of proliferative diabetic retinopathy.

61.

Arevalo JF, Maia M, Flynn HW Jr, Saravia M, Avery RL, Wu L, et al. Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy. Br J Ophthalmol. 2008;92(2):213–6. https://doi.org/10.1136/bjo.2007.127142.CrossRefPubMed

Title: Management of Complications and Vision Loss from Proliferative Diabetic Retinopathy
Authors: Gordon S. Crabtree
Jonathan S. Chang
Publication date: 01-09-2021
Publisher: Springer US
Keywords: Diabetic Retinopathy
Retinal Detachment
Diabetic Retinopathy
Published in: Current Diabetes Reports / Issue 9/2021
Print ISSN: 1534-4827
Electronic ISSN: 1539-0829
DOI: https://doi.org/10.1007/s11892-021-01396-2

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 9/2021

Toward a New Staging System for Diabetic Retinopathy Using Wide Field Swept-Source Optical Coherence Tomography Angiography

Efficacy of Ketogenic Diets on Type 2 Diabetes: a Systematic Review

Cardiovascular Risk Management in Type 1 Diabetes

Laser Therapy in the Treatment of Diabetic Retinopathy and Diabetic Macular Edema

The Role of Ultra-Widefield Fundus Imaging and Fluorescein Angiography in Diagnosis and Treatment of Diabetic Retinopathy

Molecular Aspects in the Potential of Vitamins and Supplements for Treating Diabetic Neuropathy

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials